88kDa tumorigenic growth factor and antagonists
AssigneeA&G Pharmaceutical, Inc.
InventorGinette Serrero
Life of this patent
Estimating the term…
Abstract
This invention relates to products and methods for treating cancer and for diagnosing tumorigenicity and other diseases associated with alteration in GP88 expression or action. Antagonists to an 88 KDa autocrine growth and tumorigenicity stimulator are provided which inhibit its expression or biological activity. The antagonists include antisense oligonucleotides and antibodies.
Claims10
A composition comprising a GP88 antisense oligonucleotide wherein said oligonucleotide is capable of hybridizing to at least a portion of the nucleotide sequence from nucleotide 1 to nucleotide 627 or from nucleotide 796 to nucleotide 855 or from nucleotide 1024 to nucleotide 2095 of SEQ ID NO. 16.
A method of inhibiting the production or biological activity of GP88 comprising the steps of administering ex vivo an effective amount of a GP88 antisense oligonucleotide wherein said oligonucleotide inhibits the production or biological activity of GP88.
An antisense nucleotide sequence comprising SEQ ID NO. 14.
An antisense nucleotide sequence comprising SEQ ID NO. 15.
A method of inhibiting the production or biological activity of GP88 comprising the steps of administering in vitro an effective amount of a GP88 antisense oligonucleotide wherein said oligonucleotide inhibits the production or biological activity of GP88.
Dependencies are inferred from the claim text.